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Abstract
Background: We have previously shown that c-FLIPL is a more potent inhibitor than c-FLIPS of
Fas ligand-induced apoptosis and that c-FLIPL physically binds to Daxx, an alternative Fas-signaling
adaptor. Here we examined whether c-FLIPS effectively inhibits TNFR1-mediated apoptosis and
triggers JNK activation through its interaction with TRAF2.
Results: Some cancer cell lines, such as DU145, AGS, and PC3, have higher levels of c-FLIPS than
other cell lines, such as SNU-719 and T24. The expression of c-FLIPS correlated with the
susceptibility to TNFR1-mediated apoptosis. In contrast to DU145 and PC3, which are resistant to
TNFR1-mediated apoptosis, T24 and SNU719 were sensitive to TNF-α treatment. To address the
role of c-FLIPS in TNFR1-mediated apoptosis, we examined the molecular interaction between c-
FLIPS  and TRAF2. As expected, western blot analysis revealed that TRAF2 antibody
immunoprecipitated a greater amount of c-FLIPS than c-FLIPL. Also, we measured the involvement
of c-FLIPS in TNF-α-induced JNK activation and apoptosis by comparing these in TNF-α-resistant
and TNF-α-sensitive cell lines. Treatment with TNF-α increased the phosphorylated JNK level in
SNU719 and T24 cells, whereas DU145 and AGS cells were resistant to TNF-α-mediated
apoptosis.
Conclusion: We now report that the short form of c-FLIPS is a more efficient inhibitor of TNF-
receptor 1-mediated apoptosis signaling than the long form of the protein.
Background
Tumor necrosis factor receptor 1 (TNFR1) exhibits diverse
activities inducing apoptosis and activating transcription
factor NF-κB, which lead to the induction of a number of
anti-apoptotic factors. After the components of the death-
inducing signaling complex of the related death receptor
CD95 (APO-1/Fas) [1] were identified, it was widely
assumed that TNFR1 also recruits both the FADD adaptor
and caspase 8 upon binding of its ligand, TNF-α, resulting
in the subsequent initiation of apoptosis. However, all
attempts to demonstrate a direct physical association of
FADD and caspase 8 with TNFR1 have so far been unsuc-
cessful [2], whereas the anti-apoptotic components of the
signaling complex containing TNF-α receptor-associated
factor 2 (TRAF2), TNFR1-associated death domain pro-
tein (TRADD) and c-IAP1 are readily detectable [3].
In contrast to our understanding of the FAS and TRAIL
receptors, the molecular mechanisms underlying TNFR1-
induced cell death remain poorly defined, despite exten-
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sive study of the signaling pathways that operate through
this receptor [4,5]. It is currently believed that the engage-
ment of TNFR1 triggers the recruitment of the DD-con-
taining adaptor molecule, TRADD, followed by the DD-
containing Ser/Thr kinase RIP1 [6]. This signaling com-
plex is required for TRAF2/5 and c-IAP1 binding, which
leads to triggering of the NF-κB and JNK signaling path-
ways [7]. TNFR1 binding by its ligand triggers these path-
ways, and can induce apoptosis by alternately binding the
DD-containing adaptor FADD (through TRADD), which
facilitates caspase 8 recruitment and activation [8].
The activation of the TNFR1 death receptor by TNF-α
leads to the recruitment of TRADD, which serves as a plat-
form for the formation of various signaling complexes
involved in different biological processes [7]. For
instance, TRADD can recruit FADD and promote caspase-
8 activation and apoptosis through the extrinsic pathway
[8]. However, TNF-α is not cytotoxic to most cells because
TRADD can also recruit TRAF2 and RIP to form distinct
complexes leading to the activation of NF-κB and JNK [8-
10]. Because activation of NF-κB serves as a primary mech-
anism to protect cells against apoptotic stimuli such as
TNF-α [11-13], TNF-α-induced apoptosis requires NF-κB
inhibition.
The involvement of JNK in TNF-α-mediated apoptosis is
highly controversial [14-17]. Induction of NF-κB has been
shown recently to inhibit TNF-α-mediated JNK activation.
Moreover, blocking NF-κB results in the sustained activa-
tion of JNK, which may directly promote TNF-α-mediated
apoptosis [14,17]. However, although sustained activa-
tion of JNK promotes cell death, the molecular basis of
how this contributes to TNF-α-mediated apoptosis
remains to be addressed.
One of the well described apoptosis inhibitors is c-FLIP,
which is also known as FLAME-1/I-FLICE/CASPER/
CASH/MRIT/CLARP/Usurpin [18]. c-FLIPL  and c-FLIPS
contain two DED domains that are structurally similar to
the N-terminal part of procaspase-8. The C terminus of c-
FLIPL consists of two catalytically inactive caspase-like
domains (p20 and p12), whereas the short C terminus of
c-FLIPS shows no homology to procaspases-8 or -10. Both
isoforms of c-FLIP are recruited to the DISC by DED-DED
interactions [19-21]. However, it remains to be clarified in
detail whether the differences in the mechanism of apop-
tosis inhibition also reflect different functional roles of c-
FLIPS and c-FLIPL and by which downstream mechanisms
they are mediated.
Genetic evidence suggests that FADD and caspase 8 are
important for TNFR1-mediated apoptosis [22,23]. In
addition, expression of the inhibitor of caspase 8, c-FLIPL,
inhibits the TNF-α-induced apoptotic pathway [24],
which provides further evidence for the important role of
caspase 8 in this cascade. Expression of c-FLIPL is induced
by NF-κB [25], which may explain why death receptor-
induced apoptosis is generally blocked in cells with active
NF-κB.
Here we examined whether c-FLIPS effectively inhibits
TNFR1-mediated apoptosis and triggers JNK activation
through its interaction with TRAF2. The effects of TRAF2
in TNFR1-mediated apoptosis was attenuated by DN-
TRAF2, and the level of p-JNK in c-FLIPS siRNA increased
more in TNF-α sensitive cell line than in a TNF-α resistant
cell line. In this paper, we demonstrate that the regulation
of c-FLIPS is related to the TNFR1 signaling pathway.
Results
Inhibition of TNFR1-mediated apoptosis is dependent on 
the expression levels of c-FLIPS
To examine the relationship between the expression level
of c-FLIPS and the apoptotic response, we used real-time
PCR to examine the expression of c-FLIP in human cancer
cell lines. We have shown previously that c-FLIPL is a more
potent inhibitor than c-FLIPS of Fas ligand-induced apop-
tosis and that c-FLIPL physically binds to Daxx through an
interaction between its C-terminal domain and the Fas-
binding domain of Daxx, an alternative Fas-signaling
adaptor [26]. Interestingly, some cancer cell lines, such as
DU145, AGS, and PC3, have higher levels of c-FLIPS than
other cell lines, such as SNU-719 and T24 (Fig. 1A). How-
ever, the expression of c-FLIPS at the transcriptional level
does not exactly reflect the protein levels (Fig. 1B). This
discrepancy may result from the low mRNA stability of c-
FLIP, which has been described recently [27,28].
To elucidate the biological significance of these phenom-
ena, we examined the susceptibility of these cell lines to
TNF-α. Interestingly, the expression of c-FLIPS correlated
with the susceptibility to TNFR1-mediated apoptosis (Fig.
1C). In contrast to DU145 and PC3, which are resistant to
TNFR1-mediated apoptosis, T24 and SNU719 were sensi-
tive to TNF-α treatment.
The sensitivity of cells to TNF is associated with the 
expression levels of c-FLIPS
Based on our previous findings, we speculated that the
overexpression of c-FLIPS would confer resistance to TNF-
α-induced apoptosis more effectively than overexpression
of c-FLIPL. We investigated the role of c-FLIPS in this path-
way by transfecting into SNU-719 cells, which express a
lower level of c-FLIPS than other cell lines, because we did
not have a knockout cell line of c-FLIPS. Although the
ectopic expression of c-FLIPS and c-FLIPL did not signifi-
cantly inhibit TNF-α-induced apoptosis, the inhibition of
TNFR1-induced apoptosis by c-FLIPS was more potent
than that of c-FLIPL (Fig. 2A).Journal of Molecular Signaling 2008, 3:2 http://www.jmolecularsignaling.com/content/3/1/2
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To further examine the role of c-FLIPS in JNK activation,
we transfected c-FLIPL and c-FLIPS expression vectors into
SNU-719 cells, which constitutively express TNF. We
found other significant differences in the effects of these c-
FLIP variants on the TNF-α-induced activation of JNK. In
c-FLIPL-transfected cells, TNF induced the phosphoryla-
tion of JNK, whereas in c-FLIPS-expressing cells, the phos-
phorylation of JNK was not changed (Fig. 2B). To address
the role of c-FLIPS in the activation of JNK, we examined
the molecular interaction between c-FLIPS and TRAF2, a
mediator of TNF-induced JNK and NF-κB activation.
Extracts from cell lines expressing pcDNA, c-FLIPL, and c-
FLIPS were immunoprecipitated with TRAF2 or with the
corresponding preimmune serum. As expected, western
blot analysis revealed that TRAF2 antibody immunopre-
cipitated a greater amount of c-FLIPS than c-FLIPL (Fig.
2C). To verify whether TRAF2 mediates TNFR1-induced
apoptosis, DN-TRAF2 was transiently expressed using the
same conditions as shown in Fig. 2A (Fig. 2D). The effects
on TNF-α-induced apoptosis did not differ between the c-
FLIP variants. To measure the activity of apoptosis, we
also examined the level of caspase 3 by immunoblotting
The expression levels of c-FLIPS indicate a relationship to resistance to TNF-induced apoptosis Figure 1
The expression levels of c-FLIPS indicate a relationship to resistance to TNF-induced apoptosis. (A) Immunoblot-
ting analysis of c-FLIPL and c-FLIPS in TNF-α-resistant and TNF-α-sensitive cell lines with anti-FLIPL and anti-FLIPS antibodies. 
The molecular weights of c-FLIPL and c-FLIPS were about 55 kDa and 28 kDa, respectively. β-Actin was used as a loading con-
trol. (B) Differences in the expression levels of c-FLIPS between various cancer cell lines shown by quantitative real-time PCR 
and SYBR Green detection. Levels of c-FLIPS were normalized to GAPDH and the fold changes in c-FLIPS levels are shown for 
each cell line. Data shown are the average of two assays. PCR products were analyzed using Sequence Detection software. 
Error bars equal the SEM. (C) Measurement of TNF-α-induced apoptosis using the TUNEL assay (M, TUNEL positive) in differ-
ent human cancer cell lines. Different patterns are shown following treatment with TNF-α (10 ng/ml) at 0, 12, and 24 h.Journal of Molecular Signaling 2008, 3:2 http://www.jmolecularsignaling.com/content/3/1/2
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Expression of c-FLIPS confers stronger resistance to TNF-α-induced apoptosis than c-FLIPL, through a TRAF2-dependent  mechanism Figure 2
Expression of c-FLIPS confers stronger resistance to TNF-α-induced apoptosis than c-FLIPL, through a TRAF2-
dependent mechanism. (A) Analysis of TNF-α-induced apoptosis. SNU-719 cells were transfected with the indicated con-
structs and treated with 10 ng/ml TNF-α for 24 h. Apoptotic cells were evaluated 48 h after transfection for each construct 
using the DNA fragmentation assay as described in Materials and methods. After treatment with TNF-α, the percentage of 
apoptotic cells transfected with pcDNA and c-FLIPL increased, but the percentage of apoptotic cells did not change in cells 
transfected with c-FLIPS. This experiment was performed three times independently. *P < 0.01 compared with FLIPL and FLIPS. 
(B) Ectopic expression of c-FLIPL by itself induced the activation of JNK in response to TNF-α, whereas c-FLIPS did not change 
this effect. P- and t-JNK indicate the phosphorylated JNK and total JNK levels, respectively. (C) SNU-719 cells were trans-
fected with FLAG-tagged c-FLIPL and c-FLIPS expression vectors, incubated with TNF-α (10 ng/ml) for 12 h, and subjected to 
immunoprecipitation with anti-TRAF2 antibody followed by immunoblotting with anti-FLAG antibody. Immunoblotting of 
TRAF2 was used as a loading control. (D) To verify the role of TRAF2 in TNF-α-induced apoptosis, SNU-719 cells were 
cotransfected with the indicated constructs with DN-TRAF2. Apoptotic cells were evaluated 24 h after transfection for each 
construct using flow cytometric analysis as described in Materials and methods. (E) To confirm the results, we examined cas-
pase 3 activity in the same conditions as described in Fig.2. D. β-Actin was used as a loading control.Journal of Molecular Signaling 2008, 3:2 http://www.jmolecularsignaling.com/content/3/1/2
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after treatment with DN-TRAF2. As expected, the level of
caspase 3 protein did not differ between the three c-FLIP
variants (procaspase data not shown) (Fig. 2E). These
results suggest that each c-FLIP variant is capable of bind-
ing to TRAF2, where it may inhibit TNFR1-mediated
apoptosis.
The function of c-FLIPS is exerted through TNFR1-
mediated JNK activation
The TNFR1-mediated apoptotic response has two path-
ways: type 1 apoptosis achieved through FADD-caspase 8
activation, and type 2 mitochondrial-dependent apopto-
sis, which is less-dependent on the FADD-caspase 8 path-
way [28]. TNF-α enhances the activity of JNK, which leads
to dysfunctional mitochondria and contributes to TNF-α-
induced apoptosis [29]. We examined the involvement of
c-FLIPS in TNF-α-induced JNK activation and apoptosis by
comparing these in TNF-α-resistant and TNF-α-sensitive
cell lines. Treatment with TNF-α increased the phosphor-
ylated JNK level in SNU719 and T24 cells, whereas
DU145 and AGS cells were resistant to TNF-α-mediated
apoptosis (Fig. 3A and 3B). These results indicate that the
sensitivity to TNF-α is associated with the TNF-induced
activation of JNK.
Knockdown of endogenous c-FLIPS augments TNFR1-
mediated apoptosis
To confirm the involvement of endogenous c-FLIPS in
TNFR1-mediated apoptosis, we developed siRNA oligo-
nucleotides that selectively knock down the expression of
c-FLIPS in several cancer cell lines. To select a potent can-
didate siRNA oligonucleotide, we transfected human PC3
cells, which express a higher level of c-FLIPS than other cell
lines (Fig. 1A), with siRNAs. Cells were incubated for 48
h, and the level of c-FLIPS proteins was assessed by immu-
noblot analysis (Fig. 4A). The results confirmed the ability
of oligonucleotides C2 and C3 to knock down expression
of c-FLIPS. To verify the effect of c-FLIPS knockdown on
JNK activation, we studied several cancer cell lines (Fig.
4B). Phosphorylated JNK levels increased in T24 and
SNU719 cells, whereas AGS and DU145 cells were resist-
ant to TNF-α. We also examined the susceptibility of these
cell lines to TNF-α in c-FLIPS siRNA (Fig. 4C). The basal
level of c-FLIPS was marginal in T24 and SNU719 cells,
but DU145 and AGS cell lines expressed some degree of c-
FLIPS protein in the control condition (Fig. 1A). Relative
to the basal level of c-FLIPS, the ratio of apoptosis
increased more in DU145 (7 fold) and AGS cells (6 fold)
than in T24 cells (2.5 fold), although these differences
were not considerable. Apoptosis analysis indicated that
knockdown of c-FLIPS in SNU719 and T24 cells increased
the level of spontaneous cell death by about 40% com-
pared with control, whereas knockdown of DU145 and
AGS had minimal effects. To confirm this result, we used
immunoblot analysis to examine the level of c-FLIPS pro-
tein in these cell lines after treatment with siRNA (Fig.
4D). As expected, the expression of c-FLIPS decreased in
these cell lines with c-FLIPS siRNA.
Discussion
Although a specific role for each c-FLIP and a distinct
mechanism by which each inhibits apoptosis have been
proposed [30,31], the functions of the c-FLIP splice vari-
ants remain largely unknown. Our current data provide
insight into the mechanism underlying the TNF-α-
induced apoptotic pathway. This pathway is characterized
by a higher affinity of TRAF2 for c-FLIPS over c-FLIPL and
involves suppression of JNK activation and resistance to
TNF-α-induced cell death. c-FLIPS is also readily detecta-
ble in various types of human cancer and confers resist-
ance to CD95-mediated apoptosis in T cells during the
immune response [32].
JNK activation in TNF-resistant cell lines Figure 3
JNK activation in TNF-resistant cell lines. TNF-α-sensi-
tive cell lines can activate JNK in response to TNF-α. In T24 
and SNU719 cells, JNK is activated in response to TNF-α, 
whereas DU145 and AGS cells do not show this induction. 
(A) To examine the activation of JNK, protein extracts from 
the indicated cell lines were incubated for 6 h with TNF-α 
(10 ng/ml) and subjected to immunoblotting with phospho-
specific and total JNK antibodies. P- and T- indicate phospho-
rylated proteins and total proteins, respectively. (B) Expres-
sion was quantified by densitometric scan of the blots (A). 
Values are the ratio of p-JNK and t-JNK and are presented 
relative to each control.Journal of Molecular Signaling 2008, 3:2 http://www.jmolecularsignaling.com/content/3/1/2
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Our results are summarized in the model shown in Fig. 5.
It appears that c-FLIPS and c-FLIPL have distinct roles, and
we speculate that c-FLIPS acts primarily to support TNF-
induced JNK activation. Our results are consistent with
previous data showing different functions of each type of
c-FLIP, including a specific role for c-FLIPS in CD40 sign-
aling [33]. A distinct action of each c-FLIP variant in Fas-
induced cleavage of caspase 8 has also been proposed
[34]. According to these earlier studies, c-FLIPL and c-FLIPS
produce different end products in the caspase 8 pathway.
Our data also show that apoptosis sensitivity correlates
with c-FLIP expression in several cell types, including den-
dritic cells, keratinocytes, and vascular smooth muscle
cells (data not shown).
Although TRAF2 bound both c-FLIPS and c-FLIPL in our
experiments, other reports have shown that c-FLIPL inter-
acts exclusively with TRAF2 [35]. This discrepancy may be
reconciled by recent studies showing that alternative vari-
ants of c-FLIP promote different TNF-α-induced signaling
pathways. c-FLIPL has a strong affinity for Raf, whereas c-
FLIPS is tightly associated with TRAF2 [30].
The gene knockout and siRNA knockdown studies of c-
FLIP reported to date show that reduction of both c-FLIP
variants sensitizes cells to death receptor-induced apopto-
sis [36]. We used a selective siRNA knockdown approach
to assess the specific function of endogenous c-FLIPS and
compare this with the function of c-FLIPL. Our results
reinforce the conclusion that endogenous c-FLIPS inhibits
death receptor-mediated apoptosis.
Our data showing that c-FLIPS  interacts rapidly with
FADD and enhances the activation of JNK through TRAF2
Knockdown of endogenous c-FLIPS in several cell lines enhances apoptosis induction by TNF-α Figure 4
Knockdown of endogenous c-FLIPS in several cell lines enhances apoptosis induction by TNF-α. (A) To examine 
the role of c-FLIPS in TNFR1-mediated apoptosis, PC3 cells were transfected with three different siRNA oligonucleotides 
designed to knock down c-FLIPS. The level of c-FLIPS protein was inhibited completely by C2 and C3. In further studies, we 
used C3 oligonucleotide as an siRNA. (B) The indicated siRNA-transfected cells were treated with TNF-α (5 ng/ml) for 24 h 
and extracted for immunoblotting with phospho-specific antibodies to JNK and actin. (C) The indicated siRNA-transfected cell 
lines were treated with TNF-α (5 ng/ml) for 24 h before harvesting for flow cytometric analysis. This experiment was per-
formed independently three times. (D) The indicated siRNA-transfected cell lines were treated with TNF-α (5 ng/ml) for 24 h 
and extracted for immunoblotting with anti-FLIPS antibody. β-Actin was used as a loading control.Journal of Molecular Signaling 2008, 3:2 http://www.jmolecularsignaling.com/content/3/1/2
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may explain why c-FLIPS shows high expression levels,
despite its overlapping role with c-FLIPL. In addition, the
expression pattern of c-FLIPS is coupled to the expression
of TNF. Our current experiments have confirmed our pre-
vious data showing that each type of c-FLIP has a distinct
target in the inhibition of apoptosis. We postulate that the
different expression patterns of the c-FLIP variants are spe-
cific to cancer cell type.
Methods
Cell culture and reagents
Human cancer cell lines were obtained from ATCC and
maintained in RPMI 1640 containing 10% fetal bovine
serum (FBS) (Gibco BRL) heat inactivated at 37°C; cells
were grown in a humidified chamber containing 5% CO2.
Except as indicated, all other chemicals used in this exper-
iment were purchased from Sigma-Aldrich. Recombinant
human TNF-α and antibodies were obtained from Santa
Cruz Biotech.
Construction of vectors and transfection procedure
Expression constructs for c-FLIPL, c-FLIPS, and a domi-
nant-negative version of TRAF2 (TRAF2266–501) were gen-
erated by RT-PCR-based cloning into the pcDNA 3.1 topo
His/V5 vector (Invitrogen.) Geneporter transfection rea-
gent was purchased from Gene Therapy Systems. The
transfection procedure was performed according to the
manufacturer's instructions. Briefly, cells were seeded in
six-well plates at a concentration of 1 × 105 cells/well. Four
micrograms of DNA per well was mixed with serum-free
media containing Geneporter (10 µl/well), incubated for
30 min at room temperature, and added to cells that had
previously been washed twice with PBS. After 3–5 h,
media (1 ml/well) containing 20% FBS was added to each
well. All experiments, including thymidine-incorporation
assays, western blotting, immunoprecipitation, and cell
death assays, were performed after incubation for 24 h. To
monitor transfection efficiency, cells were cotransfected
with GFP-pcDNA.
siRNA preparation and transfection
Small interfering RNA (siRNA) oligonucleotides against c-
FLIPS were synthesized by BLOCK-iT™ RNAi Designer [37]
(C1: 5'GCCATTTGACCTGCTCAAA3' C2: 5'GCAGAGATT
GGTGAGGATT3' C3: 5'GGAGAAACTAAATCTGGTT3').
All siRNA oligonucleotides were resuspended to a concen-
tration of 20 µM. The cells were seeded for transfection in
medium without antibiotics one day before transfection
to ensure they were 85%–95% confluent on the day of
transfection. For transfection, regular medium was
replaced with serum-free medium without antibiotics.
The cells were transfected with siRNA using Lipofectamine
2000 (Invitrogen) at a ratio of 1:3 siRNA:Lipofectamine
(µg:µl), giving a final concentration of 100–150 nM
siRNA. The cells were incubated with the siRNA-Lipo-
fectamine 2000 complex for 4 h, the serum-free medium
was replaced with normal medium (containing 10% FBS)
without antibiotics, and the cells incubated for a total of
48 h before further analysis.
Real-time PCR
Reactions for real-time PCR were performed in a final vol-
ume of 25 µl using TaqMan detection. Each tube con-
tained 12.5 µl of TaqMan Universal PCR Master Mix, 1.25
µl of Assays-on-Demand Gene Expression probes
(Applied Biosystems) TaqMan probe and 100 ng of each
cDNA template. All PCR samples and controls were pre-
pared in triplicate using 0.2 ml Micro-Amp Optical reac-
tion tubes and MicroAmp Optical tube caps (Applied
Biosystems). The PCR mixture was held at 50°C for 5 min
and denatured at 95°C for 10 min. Forty amplification
cycles were carried out at 95°C for 20 s, followed by 60°C
for 1 min. All amplifications were performed using an ABI
PRISM® 7900 HT (Applied Biosystems). PCR products
A working model of the role of c-FLIPS in TNFR1-mediated  apoptosis Figure 5
A working model of the role of c-FLIPS in TNFR1-
mediated apoptosis. The binding of c-FLIPS to TRAF2 
delays the recruitment of c-FLIPL, and c-FLIPS and c-FLIPL 
block TNFR1-mediated apoptosis. However, the cellular c-
FLIPS level is elevated sufficiently to block apoptosis and pro-
mote cell survival.Journal of Molecular Signaling 2008, 3:2 http://www.jmolecularsignaling.com/content/3/1/2
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were analyzed using Sequence Detection software
(Applied Biosystems).
Cell death assay and flow cytometric detection of 
apoptosis by annexin V labeling
A DNA fragmentation assay (BMS; Manheim, Germany)
was used. All procedures were performed using the manu-
facturer's protocol. Analysis of ELISA was carried by a Soft-
max ELISA reader at an absorbance of 460 nm. Each
experiment was performed independently three times by
external observers.
Annexin V (Sigma), a phosphatidylserine-binding pro-
tein, was used to detect apoptotic cells, and the nuclear
stain, propidium iodide (PI) (Sigma) was used to identify
late-apoptotic cells or necrotic cells. Cells seeded at a con-
centration of 1 × 105 cells/well in six-well plates were incu-
bated at 37°C with or without 10 ng/ml TNF-α for 24 h.
Cells were washed twice with cold PBS and resuspended
in 500 µl of binding buffer (100 µM HEPES, pH 7.4, 14
mM NaCl, and 25 µM CaCl2) containing 5 µl of annexin
V-fluorescein isothiocyanate (FITC) (Sigma) and 10 µg/
ml PI for 15 min at 4°C in the dark. For each sample,
about 105 cells were analyzed by flow cytometry. FITC and
PI emissions were collected through 520 and 630 nm
bandpass filters, respectively.
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